Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Silvia Rios Romenets

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Neurology|August 3, 2012
Caffeine for treatment of Parkinson disease: a randomized controlled trialRonald B Postuma, Anthony E Lang, Renato P Munhoz, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 27, 2018
Validation of the MDS clinical diagnostic criteria for Parkinson's diseaseRonald B Postuma, Werner Poewe, Irene Litvan, et al.
Journal of Alzheimer'S Disease : JAD|September 14, 2020
Examining Sex Differences in Markers of Cognition and Neurodegeneration in Autosomal Dominant Alzheimer's Disease: Preliminary Findings from the Colombian Alzheimer's Prevention Initiative Biomarker StudyClara Vila-Castelar, Edmarie Guzmán-Vélez, Enmanuelle Pardilla-Delgado, et al.
Applied Neuropsychology. Adult|June 25, 2019
Normative data stratified by age and education for a Spanish neuropsychological test battery: Results from the Colombian Alzheimer's prevention initiative registryValeria L Torres, Clara Vila-Castelar, Yamile Bocanegra, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 30, 2018
The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical <i>PSEN1</i> E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohortPierre N Tariot, Francisco Lopera, Jessica B Langbaum, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 6, 2023
Sex differences in blood biomarkers and cognitive performance in individuals with autosomal dominant Alzheimer's diseaseClara Vila-Castelar, Yinghua Chen, Stephanie Langella, et al.
The Lancet. Neurology|May 30, 2020
Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort studyYakeel T Quiroz, Henrik Zetterberg, Eric M Reiman, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 14, 2022
A public resource of baseline data from the Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease TrialEric M Reiman, Jeremy J Pruzin, Silvia Rios-Romenets, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 30, 2025
Plasma p-tau231 in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: A cross-sectional and longitudinal cohort studyVincent Malotaux, Nicholas J Ashton, Annika Öhrfelt, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 27, 2018
Movement disorder society criteria for clinically established early Parkinson's diseaseDaniela Berg, Charles H Adler, Bastiaan R Bloem, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Neurology|August 3, 2012
Caffeine for treatment of Parkinson disease: a randomized controlled trialRonald B Postuma, Anthony E Lang, Renato P Munhoz, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 27, 2018
Validation of the MDS clinical diagnostic criteria for Parkinson's diseaseRonald B Postuma, Werner Poewe, Irene Litvan, et al.
Journal of Alzheimer'S Disease : JAD|September 14, 2020
Examining Sex Differences in Markers of Cognition and Neurodegeneration in Autosomal Dominant Alzheimer's Disease: Preliminary Findings from the Colombian Alzheimer's Prevention Initiative Biomarker StudyClara Vila-Castelar, Edmarie Guzmán-Vélez, Enmanuelle Pardilla-Delgado, et al.
Applied Neuropsychology. Adult|June 25, 2019
Normative data stratified by age and education for a Spanish neuropsychological test battery: Results from the Colombian Alzheimer's prevention initiative registryValeria L Torres, Clara Vila-Castelar, Yamile Bocanegra, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 30, 2018
The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical <i>PSEN1</i> E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohortPierre N Tariot, Francisco Lopera, Jessica B Langbaum, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 6, 2023
Sex differences in blood biomarkers and cognitive performance in individuals with autosomal dominant Alzheimer's diseaseClara Vila-Castelar, Yinghua Chen, Stephanie Langella, et al.
The Lancet. Neurology|May 30, 2020
Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort studyYakeel T Quiroz, Henrik Zetterberg, Eric M Reiman, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 14, 2022
A public resource of baseline data from the Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease TrialEric M Reiman, Jeremy J Pruzin, Silvia Rios-Romenets, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 30, 2025
Plasma p-tau231 in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: A cross-sectional and longitudinal cohort studyVincent Malotaux, Nicholas J Ashton, Annika Öhrfelt, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 27, 2018
Movement disorder society criteria for clinically established early Parkinson's diseaseDaniela Berg, Charles H Adler, Bastiaan R Bloem, et al.
Pageof 3